HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer identifier:
NCT03685331 (


Study Contact Information:

Contact: Payal D. Shah, MD by phone:  855-216-0098
Alexandra Torres by phone: 855-216-0098
or Email: [email protected]  

About the Study

The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

Type of Study

Phase I of this study is a non-randomized, dose-escalation study to find the ideal dose of Palbociclib. 

Phase II study is non-randomized study where participants will receive the dose of Palbociclib determined by Phase 1. 

What the Study Entails

Patients enrolled in Phase 1 will receive:

Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent.

Study participants will be followed for an estimated average of 7 months.

Study Site

Pennsylvania, Philadephia
Abramson Cancer Center of the University of Pennsylvania
Contact: Payal D. Shah, MD by phone  855-216-0098  or [email protected]  

This Study is Open To:

Men and women age 18 years and older can be considered for enrollment in this study if they have:

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.